Your browser doesn't support javascript.
loading
Panitumumab Associated Acute Pancreatitis.
Arbag, Huseyin Can; Sumbul, Hilmi Erdem; Buyuksimsek, Mahmut; Ogul, Ali; Yetisir, Abdullah Evren; Koseci, Tolga; Bozkurt Duman, Berna; Tohumcuoglu, Mert; Kesen, Oguzhan; Cil, Timucin.
Afiliação
  • Arbag HC; Department of Internal Medicine, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
  • Sumbul HE; Department of Internal Medicine, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
  • Buyuksimsek M; Department of Medical Oncology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
  • Ogul A; Department of Medical Oncology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
  • Yetisir AE; Department of Medical Oncology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
  • Koseci T; Department of Medical Oncology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
  • Bozkurt Duman B; Department of Medical Oncology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
  • Tohumcuoglu M; Department of Medical Oncology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
  • Kesen O; Department of Medical Oncology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
  • Cil T; Department of Medical Oncology, University of Health Sciences-Adana Health Practice and Research Center, Adana, Turkey.
J Oncol Pharm Pract ; 28(5): 1207-1208, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35037780
ABSTRACT

INTRODUCTION:

The addition of panitumumab to chemotherapy in wild-type metastatic colon cancer contributes to survival. While the skin related side effects of panitumumab are well known, we wanted to present a case where it was a possible cause of acute pancreatitis. CASE REPORT The FOLFOX regimen was started in a 67-year-old patient with sigmoid colon cancer and multiple liver metastases. After 2 cycles, genetic tests were concluded and panitumumab 6 mg/kg was added to the treatment. The patient who presented with abdominal pain 2 days after the treatment was hospitalized with acute pancreaatitis. MANAGEMENT &

OUTCOME:

Abdominal tomography of the patient was compatible with acute pancreatitis. Oral intake was stopped, IV hydration was started. The patient, whose complaints regressed, was discharged on the 3rd day of hospitalization.

DISCUSSION:

Skin side effects related to panitumumab are observed quite frequently. Although panitumumab related gastrointestinal side effects have been reported, there is no data on acute pancreatitis. Panitumumab was added to the chemotherapy regimen he received, and it was thought that panitumumab might be the etiological factor in the case who developed pancreatitis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pancreatite / Neoplasias Colorretais / Neoplasias do Colo Tipo de estudo: Risk_factors_studies Limite: Aged / Humans / Male Idioma: En Revista: J Oncol Pharm Pract Assunto da revista: FARMACIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Turquia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pancreatite / Neoplasias Colorretais / Neoplasias do Colo Tipo de estudo: Risk_factors_studies Limite: Aged / Humans / Male Idioma: En Revista: J Oncol Pharm Pract Assunto da revista: FARMACIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Turquia